Archer C, Randhawa M, Kim H, et al. Real world data on intensive follow-up for stage IV metastatic melanoma patients receiving ipilimumab and nivolumab: a safer model of care? SMR 2017, abstract P07-1.
FDA keurt pembrolizumab goed voor adjuvante behandeling stadium IIB/IIC-melanoom
dec 2021 | Dermato-oncologie, Immuuntherapie